Search

Author/Creator Blaettler, Thomas

1. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. (12th January 2015)

Authors:
Feuerbach, Dominik; Pezous, Nicole; Weiss, Markus; Shakeri‐Nejad, Kasra; Lingenhoehl, Kurt; Hoyer, Daniel; Hurth, Konstanze; Bilbe, Graeme; Pryce, Christopher R; McAllister, Kevin; Chaperon, Frederique; Kucher, Klaus; Johns, Donald; Blaettler, Thomas; Lopez Lopez, Cristina
Journal:
British journal of pharmacology
Issue:
Volume 172:Number 5(2015:Mar.)
Page Start:
1292
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. (December 2016)

Authors:
Bugarski-Kirola, Dragana; Iwata, Nakao; Sameljak, Snjezana; Reid, Carol; Blaettler, Thomas; Millar, Laurie; Marques, Tiago Reis; Garibaldi, George; Kapur, Shitij
Journal:
Lancet
Issue:
Volume 3:Number 12(2016)
Page Start:
1115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment. Issue 6 (7th September 2021)

Authors:
Mengel, Eugen; Patterson, Marc C.; Da Riol, Rosalia M.; Del Toro, Mireia; Deodato, Federica; Gautschi, Matthias; Grunewald, Stephanie; Grønborg, Sabine; Harmatz, Paul; Héron, Bénédicte; Maier, Esther M.; Roubertie, Agathe; Santra, Saikat; Tylki‐Szymanska, Anna; Day, Simon; Andreasen, Anne Katrine...
Journal:
Journal of inherited metabolic disease
Issue:
Volume 44:Issue 6(2021)
Page Start:
1463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer's Disease. (1st July 2016)

Authors:
Blaettler, Thomas; Smith, Janice; Smith, Jillian; Paul, Robert; Asnaghi, Veronica; Fuji, Reina; Quartino, Angelica; Honigberg, Lee; Rabbia, Michael A.; Yule, Susan; Ostrowitzki, Susanne; Fontoura, Paulo
Journal:
Alzheimer's & dementia
Issue:
Volume 12:Supplement 7S(2016)Part 12
Page Start:
P609
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Issue 7 (July 2017)

Authors:
Bertini, Enrico; Dessaud, Eric; Mercuri, Eugenio; Muntoni, Francesco; Kirschner, Janbernd; Reid, Carol; Lusakowska, Anna; Comi, Giacomo P; Cuisset, Jean-Marie; Abitbol, Jean-Louis; Scherrer, Bruno; Ducray, Patricia Sanwald; Buchbjerg, Jeppe; Vianna, Eduardo; van der Pol, W Ludo; Vuillerot, Carole...
Journal:
Lancet neurology
Issue:
Volume 16:Issue 7(2017:Jul.)
Page Start:
513
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗